Dec 30, 2025 • Research Tree
BULLISH
Hutchmed China Ltd - China NDA Acceptance-Savolitinib in Gastric Cancer
HUTCHMED announced that its New Drug Application (NDA) for savolitinib, a selective MET inhibitor, for the treatment of MET-amplified gastric cancer has been accepted with priority review in China. This milestone follows positive Phase II study data and a Breakthrough Therapy Designation in 2023, positioning savolitinib as a potential first-in-class treatment for a challenging form of gastric cancer. Savolitinib, developed with AstraZeneca, is already approved in China for other indications and is included in the National Reimbursement Drug List.
Dec 30, 2025 • Stock Titan
SOMEWHAT-BULLISH
China fast-tracks review of drug for MET-amplified gastric cancer
HUTCHMED (HCM) has received priority review status for its New Drug Application (NDA) for savolitinib in China for the treatment of locally advanced or metastatic gastric cancer patients with MET amplification. The NDA is supported by positive Phase II registration study data in Chinese patients and follows a Breakthrough Therapy Designation granted in 2023. This drug has the potential to be the first selective MET inhibitor specifically for this indication in China, addressing an estimated 18,000 annual cases.
Dec 30, 2025 • Investing.com South Africa
BULLISH
China approves priority review for HUTCHMED’s liver cancer drug By Investing.com
HUTCHMED (China) Limited announced that Chinese regulators have granted priority review for its new drug application for fanregratinib, a liver cancer drug. This drug is intended for patients with advanced or unresectable intrahepatic cholangiocarcinoma (ICC) with specific genetic fusions. The application is supported by positive Phase II study data, and HUTCHMED retains worldwide rights to the drug.
Dec 30, 2025 • TradingView — Track All Markets
NEUTRAL
REG - Hutchmed China Ltd - Blocklisting Six Monthly Return
HUTCHMED (China) Limited has announced its blocklisting six-monthly return for the period from June 29, 2025, to December 28, 2025. The report details the status of its 2015 Share Option Scheme, showing 216,150 securities issued during the period and a balance of 45,775,868 ordinary shares not yet issued. The total number of securities in issue at the end of the period is 872,327,620 ordinary shares.
Dec 29, 2025 • Investing.com India
BULLISH
China approves priority review for HUTCHMED’s liver cancer drug
HUTCHMED (China) Limited announced that Chinese regulators have granted priority review for its new drug application for fanregratinib, a liver cancer drug. The drug is intended to treat advanced intrahepatic cholangiocarcinoma (ICC) in patients with specific genetic rearrangements who have undergone prior systemic therapy. This approval is based on positive data from a Phase II registration study conducted in China.
Dec 29, 2025 • Quiver Quantitative
BULLISH
HUTCHMED Announces Priority Review of NDA for Fanregratinib in Treatment of Advanced Intrahepatic Cholangiocarcinoma in China
HUTCHMED (China) Limited announced that its New Drug Application (NDA) for fanregratinib (HMPL-453), an oral inhibitor targeting FGFR 1/2/3 for advanced intrahepatic cholangiocarcinoma (ICC), has been accepted for priority review by China's NMPA. This priority review is supported by positive results from a Phase II trial in China that met its primary endpoint of objective response rate. HUTCHMED retains all worldwide rights to fanregratinib, a therapy for a highly aggressive form of liver cancer with poor long-term survival.